Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 5 minute read Pharma Industry News Novo Nordisk and Septerna forge $2.2bn GPCR deal to develop oral therapies for obesity and diabetes Novo Nordisk partners with Septerna in a $2.2B deal to develop oral GPCR therapies for obesity and diabetes. Explore the full stock sentiment and deal impact. byPallavi MadhirajuMay 14, 2025